IRVINE--- China's Anti-Cancer Drug Market Forecast Exceeded $3.5 Billion in 2007, According to a New Report from Windhover Infor
IRVINE, Calif.--(BUSINESS WIRE)--According to the Chinese Ministry of Health (MOH), there are approximately 2.13 million patients with newly diagnosed tumors (both benign and malignant) each year, of which 1.06 million are newly diagnosed cancer patients. Cancer has become the leading cause of mortality in both urban and rural China. According to national statistics data, the cancer mortality rate of urban Chinese residents is currently 140.47 per 100,000 (21.82% of all urban deaths) and the cancer mortality rate of rural Chinese residents was 111.57 per 100,000 (16.50% of all rural deaths).
In the Chinese hospital drug market, sales of anti-cancer drugs have risen steadily in recent years. During 2003-2005, the annual compound growth rate of anti-cancer drug sales was approximately 24.5%. In 2006, due to the national campaign on anti-commercial bribery as well as other related government policies, the market growth of anti-cancer drugs slowed down to approximately 11.1%; however, the growth of the anti-cancer drug market regained momentum and reached an annual growth rate of approximately 22.2% in 2007. The total market size for anti-cancer drugs in 2007 was 25.5 billion RMB (3.6 billion USD).
Major topics covered in this report include: Summary of Global Markets of Anti-Cancer Drugs, Summary of Anti-Cancer Drugs in China, Market Analysis of China’s Anti-Cancer Drugs, List of Brand Names, Generic Names of Anti-Cancer Drugs and their Corresponding Manufacturers in China, Packaging and Pricing of Anti-Cancer Drugs in China, Anti-Cancer Drugs on the National Healthcare Insurance Coverage list, Regulatory and Government Policies for Anti-Cancer Drugs in China, Current Anti-Cancer Drugs in China, and Current Anti-Cancer Drug Development in China.
Companies covered include: Jiangsu Hansen Pharmaceutical Co., Ltd.(Hansen Pharma), Jiangsu Hengrui Medicine Co., Ltd., Novartis, Pfizer, Roche, sanofi-aventis, Sichuan Diao Jiuhong Group, Pharmaceutical Co, AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Guizhou Baiqiang, Pharmaceutical Co., Ltd., Hainan Zhonghe Pharmaceutical Co., Ltd, Jinling Pharmaceutical Co. Ltd., Livzon Pharmaceutical Group Inc., Nanjing Kanghai Pharmaceutical Co., Ltd., Nanjing Sike Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., SciClone Pharmaceuticals Italy S.R.L., Shenzhen Wanle Pharmaceutical Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. A full table of contents and ordering information can be viewed at http://www.medtechinsight.com/ReportDHP9000.html.
Windhover Information has also recently published a variety of additional Pharmaceutical/Drug Delivery market analyses, covering topics such as stroke management, benign prostatic hyperplasia, erectile dysfunction, urinary incontinence, drug delivery and pain management products to name a few. You can view these and many other reports covering 25 high-growth device specialty areas at http://www.medtechinsight.com/reports.html.
Windhover Information provides pharmaceutical, the medical device, healthcare-related industries, or development and investment industries with consistent, comprehensive and meticulously researched market analysis that incorporates strategic vision and a thorough understanding of competing technologies. For more on the company’s products and services please visit www.medtechinsight.com. To inquire or to order this report for immediate delivery, simply call one of the numbers listed below.